Feedback (LON:FDBK) shares surged as the medical imaging software company, revealed it is discussing hooking up with imaging services leader Alliance Medical Group.
The intention is to integrate Feedback's TexRAD texture analysis software into Alliance's lung cancer imaging service.
Although the technical discussions are at a very early stage, this is considered by Feedback to be potentially of great significance as regards the future commercialisation of TexRAD software.
Alliance and Feedback plan to undertake a multi-centre imaging research study to assess the use of TexRAD in lung cancer, with the eventual aim of gaining National Institute for Health and Care Excellence approval for TexRAD to be used in the lung cancer pathway..
“The planned research study in lung cancer will be an important step towards the future commercialisation of TexRAD," said Dr Balaji Ganeshan, chief executive of TexRAD and director of New Business at Feedback.